Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

6(66.7%)

Phase 3

1(11.1%)

N/A

1(11.1%)

Phase 4

1(11.1%)

9Total

Phase 2(6)

Phase 3(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06603311Not ApplicableActive Not Recruiting

Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

Role: collaborator

NCT02375906Completed

The Hepatitis Delta International Network

Role: lead

NCT03818308Phase 2Completed

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Role: collaborator

NCT03282474Phase 2Completed

HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

Role: collaborator

NCT00932971Phase 2Completed

HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis

Role: lead

NCT02309918Phase 2Completed

HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection

Role: lead

NCT00803309Phase 4Terminated

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients

Role: lead

NCT01046799Phase 3Completed

Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir

Role: lead

NCT01258023Phase 2Completed

Seasonal Flu Vaccine in Adult Transplant Recipients

Role: lead

NCT01069601Phase 2Terminated

H1N1sw Vaccine in Adult Transplant Recipients

Role: lead

All 10 trials loaded